Genetics & Genomics

FDA Recommends Genetic Testing for Coumadin Patients; PGXL Laboratories Cited on ABC 'World News Tonight'

Published in Medical Letter on the CDC and FDA, September 16th, 2007

In a milestone decision on August 17, 2007, the FDA announced important changes in the warfarin label (also known as Coumadin), recommending that a lower initial Coumadin dose "should be considered for patients with certain genetic variations." Coumadin is a commonly prescribed blood thinner with an extremely narrow safe-dosage range varying dramatically from patient to patient.

Patients who take a dose larger than they can tolerate are at risk of life-threatening bleeding events, according to the FDA. Coumadin complications are responsible for about 30,000 emergency room visits a year in the United States. Simple genetics testing done at the beginning of Coumadin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry